AU Patent

AU2022357570A1 — Methods of treating cancer and the pharmaceutical compositions thereof

Assigned to Systimmune Inc · Expires 2024-04-11 · 2y expired

What this patent protects

A method for treating cancer in a subject comprising, administering to the subject a bispecific antibody having a binding specificity to EGFR and HER3 and a therapeutic agent, wherein the therapeutic agent comprises a tyrosine kinase inhibitor (TKI), an alkylating agent, an anti-…

USPTO Abstract

A method for treating cancer in a subject comprising, administering to the subject a bispecific antibody having a binding specificity to EGFR and HER3 and a therapeutic agent, wherein the therapeutic agent comprises a tyrosine kinase inhibitor (TKI), an alkylating agent, an anti-metabolite, an anti-microtubule agent, a cytotoxic antibiotic, a topoisomerase inhibitor, a chemoprotectant, or a combination thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022357570A1
Jurisdiction
AU
Classification
—
Expires
2024-04-11
Drug substance claim
No
Drug product claim
No
Assignee
Systimmune Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.